GREY:IMVIF - Post Discussion
Post by
Hideaway on Feb 14, 2023 5:37pm
IO 360 Agenda
Delivery Matters: Leveraging the DPX Cancer Vaccine Platform to Educate
Sustained Anti-cancer Immunity and Durable Clinical Benefit
This talk addresses:
- The unique capability of the DPX vaccine platform to package diverse immune cargo (Neo- and tumor-associated antigens, immune modulators) into a single formulation for delivery to APCs and flow through lymph nodes.
- The phase 2 clinical experience with the lead DPX asset, Maveropepimut-S (MVP-S), shows clear evidence of sustained immune response and deep, durable clinical benefit.
- Updates on patient responses including complete responses in relapsed/ refractory
DLBCL, advanced ovarian cancers and metastatic bladder cancers.
Jeremy Graff, PhD
CSO. IMV Inc
According to the IO 360 Conference agenda,there was supposed to be an update on the ovarian and bladder cancers in addition to DLBC.
Why was there no update?
Failure to meet expectations combined with the sparse DLBCL report have contributed to our sad state today as well as the lack of conditions in the last financing.
Be the first to comment on this post